Details of Disease

General Information of Disease (ID: DIS17SNY)

• Disease Name: Epithelioid mesothelioma
• Synonyms: epithelioid mesothelioma; malignant epithelial mesothelioma; epithelioid mesothelioma, malignant; epithelioid mesothelioma, malignant (morphologic abnormality); epithelial mesothelioma
• Disease Class: 2F10: Mesothelial tumour
• Definition: A malignant neoplasm arising from mesothelial cells in the pleura. It is characterized by the presence of neoplastic cells with an epithelioid appearance. In the majority of cases, the neoplastic epithelioid cells lack significant cytologic atypia; mitotic figures are infrequently seen. In a minority of cases, the neoplastic cells are poorly differentiated and there is evidence of nuclear atypia and increased mitotic activity.
• Disease Hierarchy:
  DISTHJGH: Malignant mesothelioma
  DIS17SNY: Epithelioid mesothelioma
• ICD Code: ICD-11: ICD-11: 2F10
• Disease Identifiers:
  MONDO ID: MONDO_0005599
  UMLS CUI: C0862312
  MedGen ID: 163578
  SNOMED CT ID: 65278006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cisplatin	DMRHGI9	Approved	Small molecular drug	[1]
Pemetrexed	DMMX2E6	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
227Th-labelled MSLN-TTC	DM1ZY6M	Phase 1	Radiopharmaceutical therapy agent	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MSLN	TT4RXME	Strong	Altered Expression	[4]

This Disease Is Related to 7 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CLDN15	OT9K0KI7	Limited	Altered Expression	[5]
EFEMP2	OT0I2B4J	Limited	Altered Expression	[6]
ITLN1	OT7ZLJVV	Limited	Biomarker	[7]
MUC21	OTQ8GP5L	Limited	Altered Expression	[8]
SPPL2A	OTCVF6MM	Limited	Biomarker	[9]
TRIP6	OTIPA4ZR	Limited	Altered Expression	[6]
GPC1	OTQKRSSV	Strong	Altered Expression	[10]

References

• [1] Cisplatin FDA Label
• [2] Pemetrexed FDA Label
• [3] ClinicalTrials.gov (NCT03507452) First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin. U.S. National Institutes of Health.
• [4] Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.Clin Colorectal Cancer. 2019 Sep;18(3):192-199.e1. doi: 10.1016/j.clcc.2019.06.006. Epub 2019 Jul 2.
• [5] Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.Ann Diagn Pathol. 2015 Aug;19(4):193-7. doi: 10.1016/j.anndiagpath.2015.03.007. Epub 2015 Apr 14.
• [6] Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma.Gene. 2013 Mar 15;517(1):99-105. doi: 10.1016/j.gene.2012.12.075. Epub 2013 Jan 9.
• [7] Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma.Am J Surg Pathol. 2017 Aug;41(8):1045-1052. doi: 10.1097/PAS.0000000000000852.
• [8] Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.Histopathology. 2019 Mar;74(4):545-554. doi: 10.1111/his.13775. Epub 2019 Jan 15.
• [9] Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.Pathobiology. 2016;83(1):33-40. doi: 10.1159/000442092. Epub 2016 Jan 7.
• [10] Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.Mod Pathol. 2018 May;31(5):809-815. doi: 10.1038/modpathol.2017.190. Epub 2018 Jan 12.